Indaptus Therapeutics (INDP) Competitors $11.19 +0.04 (+0.36%) Closing price 03:55 PM EasternExtended Trading$11.69 +0.50 (+4.47%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock INDP vs. MRNS, MAAQ, GRCE, ALLK, RANI, INKT, DYAI, SCYX, SXTC, and ENLVShould you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include Marinus Pharmaceuticals (MRNS), Mana Capital Acquisition (MAAQ), Grace Therapeutics (GRCE), Allakos (ALLK), Rani Therapeutics (RANI), MiNK Therapeutics (INKT), Dyadic International (DYAI), SCYNEXIS (SCYX), China SXT Pharmaceuticals (SXTC), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical products" industry. Indaptus Therapeutics vs. Its Competitors Marinus Pharmaceuticals Mana Capital Acquisition Grace Therapeutics Allakos Rani Therapeutics MiNK Therapeutics Dyadic International SCYNEXIS China SXT Pharmaceuticals Enlivex Therapeutics Marinus Pharmaceuticals (NASDAQ:MRNS) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk. Do institutionals & insiders believe in MRNS or INDP? 98.8% of Marinus Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 5.5% of Marinus Pharmaceuticals shares are owned by company insiders. Comparatively, 20.6% of Indaptus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, MRNS or INDP? Marinus Pharmaceuticals has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.35, suggesting that its share price is 35% more volatile than the S&P 500. Does the media refer more to MRNS or INDP? In the previous week, Indaptus Therapeutics had 5 more articles in the media than Marinus Pharmaceuticals. MarketBeat recorded 5 mentions for Indaptus Therapeutics and 0 mentions for Marinus Pharmaceuticals. Indaptus Therapeutics' average media sentiment score of 0.37 beat Marinus Pharmaceuticals' score of 0.00 indicating that Indaptus Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Marinus Pharmaceuticals Neutral Indaptus Therapeutics Neutral Do analysts rate MRNS or INDP? Marinus Pharmaceuticals presently has a consensus price target of $3.92, indicating a potential upside of 613.29%. Indaptus Therapeutics has a consensus price target of $238.00, indicating a potential upside of 2,026.90%. Given Indaptus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Indaptus Therapeutics is more favorable than Marinus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marinus Pharmaceuticals 0 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.40Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, MRNS or INDP? Indaptus Therapeutics has lower revenue, but higher earnings than Marinus Pharmaceuticals. Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Marinus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMarinus Pharmaceuticals$30.99M0.98-$141.40M-$2.47-0.22Indaptus TherapeuticsN/AN/A-$15.02M-$1.49-7.51 Is MRNS or INDP more profitable? Indaptus Therapeutics has a net margin of 0.00% compared to Marinus Pharmaceuticals' net margin of -446.48%. Indaptus Therapeutics' return on equity of -333.02% beat Marinus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Marinus Pharmaceuticals-446.48% -7,831.35% -120.74% Indaptus Therapeutics N/A -333.02%-216.36% SummaryIndaptus Therapeutics beats Marinus Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get Indaptus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INDP vs. The Competition Export to ExcelMetricIndaptus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.38M$2.42B$5.54B$8.87BDividend YieldN/A1.77%5.39%4.10%P/E Ratio-0.278.7226.1419.88Price / SalesN/A663.86414.67113.66Price / CashN/A151.5836.1356.90Price / Book1.034.548.055.38Net Income-$15.02M$31.16M$3.15B$248.50M7 Day Performance8.60%0.15%1.85%2.97%1 Month Performance17.40%8.81%4.81%6.02%1 Year Performance-81.50%2.55%34.86%20.39% Indaptus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INDPIndaptus Therapeutics3.0528 of 5 stars$11.19+0.4%$238.00+2,026.9%-82.0%$6.38MN/A-0.276News CoverageGap DownMRNSMarinus Pharmaceuticals2.2716 of 5 stars$0.55-0.2%$3.92+613.3%-57.1%$30.32M$30.99M-0.22110MAAQMana Capital AcquisitionN/A$3.71-4.6%N/A+554.5%$30.14MN/A0.001Gap UpGRCEGrace Therapeutics2.1862 of 5 stars$2.96+1.0%$12.00+305.4%N/A$30.01MN/A-2.55N/APositive NewsALLKAllakos2.8267 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190RANIRani Therapeutics2.2325 of 5 stars$0.51+3.5%$7.33+1,346.4%-86.6%$29.14M$1.03M-0.51110Positive NewsINKTMiNK Therapeutics3.4156 of 5 stars$7.34+1.0%$37.50+411.2%-18.9%$29.03MN/A-2.8930Positive NewsGap DownDYAIDyadic International2.6237 of 5 stars$0.96+1.9%$6.00+527.6%-36.6%$28.77M$3.49M-4.787News CoverageSCYXSCYNEXIS0.7542 of 5 stars$0.73+0.4%N/A-64.1%$28.72M$3.75M-1.3160Positive NewsGap UpSXTCChina SXT Pharmaceuticals0.3514 of 5 stars$1.81-1.9%N/A-77.1%$28.19M$1.93M0.0090Gap DownENLVEnlivex Therapeutics3.3196 of 5 stars$1.18+1.3%$10.00+751.1%-18.8%$27.79MN/A-1.7870Gap Up Related Companies and Tools Related Companies MRNS Alternatives MAAQ Alternatives GRCE Alternatives ALLK Alternatives RANI Alternatives INKT Alternatives DYAI Alternatives SCYX Alternatives SXTC Alternatives ENLV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INDP) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored"I'm risking my reputation on this"Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the sa...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
